Evidence map›Paper›PMID 36677690›Full record

ArticleMolecules (Basel, Switzerland)2023

Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.

Adrien Djiemeny Ngueta, Jenny Roy, René Maltais, Donald Poirier

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Adrien Djiemeny NguetaLaboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec Research Center-Université Laval, Quebec, QC G1V 4G2, Canada.
Jenny RoyLaboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec Research Center-Université Laval, Quebec, QC G1V 4G2, Canada.
René MaltaisLaboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec Research Center-Université Laval, Quebec, QC G1V 4G2, Canada.ORCID 0000-0002-0394-1653
Donald PoirierLaboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec Research Center-Université Laval, Quebec, QC G1V 4G2, Canada.ORCID 0000-0002-7751-3184
Université Laval · CA

Funding

CHU de Québec Research Center-Université Laval (Endocrinology and Nephrology Unit) N/A
6 · The paper itself

Abstract

Estradiol (E2) plays an important role in the progression of diseases such as breast cancer and endometriosis. Inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), the enzyme that catalyzes the last step in the biosynthesis of the estrogenic hormone E2, therefore constitutes an interesting approach for the treatment of these two estrogen-dependent diseases. In order to obtain new inhibitors of 17β-HSD1, the impact of a

Indexed as

17-Hydroxysteroid DehydrogenasesBreast NeoplasmsEndometriosisEnzyme InhibitorsCell Line, TumorEstradiolEstrogensEstroneFemaleHumansMolecular Docking Simulation17-Hydroxysteroid Dehydrogenases3 (or 17)-beta-hydroxysteroid dehydrogenaseEnzyme InhibitorsEstradiolEstrogensEstrone17β-HSD1chemical synthesisestrogeninhibitorsteroid

Identifiers

PMID36677690
PMCPMC9862175
OpenAlexW4313890108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.